drugset / Trial / NCT01111448
Temsirolimus in Myelodysplastic Syndrome (MDS)
Phase 2
Terminated
20 enrolled
Technical University Dresden
Wyeth is now a wholly owned subsidiary of Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this Pilot-study is to evaluate the response of unselected MDS patients to temsirolimus a drug approved for the treatment of renal cell cancer. It is planned to give temsirolimus at a weekly dose of 25 mg as intravenous infusion for a maximum duration of 12 months. Regular bone marrow biopsies are planned for controlling MDS response.
Timeline
- Start
- 2010-04
- Primary completion
- 2013-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temsirolimus | Small molecule | 25 mg | Intravenous |